The decision to stop the trial
The IMpactMF trial enrolled 327 patients with high-risk myelofibrosis whose disease had returned or failed to respond after treatment with a JAK inhibitor, a type of drug used to manage symptoms and reduce spleen enlargement.
According to Geron, the independent data monitoring committee concluded the trial was unlikely to achieve its primary goal of overall survival compared with the best available therapy.
The company said it would conduct a detailed analysis of the data and share the findings later.

















